FORMULATION : REGULATED MARKETS
More Reyra manufactures and supplies a range of immunosuppressant finished products to the U.S. market. Our partnership-driven business model allows us to leverage our strengths in product development and manufacturing, while our partners capitalize on their expertise in marketing these products.
We have launched ANDA’s successfully in the USA and have a robust pipeline of products that we plan to commercialize in the coming years to ensure strong growth in the future.
We are actively exploring opportunities to partner with companies in different regions through various business models like out-licensing and co-marketing. Our goal is to deliver high-quality, bio-equivalent finished products to patients.
| Sr. No | Product Name | ANDA# | Approval Date | Pack Style |
|---|---|---|---|---|
| 1 | Mycophenolate Mofetil Capsules, USP 250mg | 210181 | 8-Jan-19 | 100 counts in HDPE bottles 500 counts in HDPE bottles |
| 2 | Mycophenolic Acid DR Tablets USP, 180 mg and 360 mg | 211173 | 13-Dec-19 | 120 counts in HDPE bottles |
| 3 | Mycophenolate Mofetil Tablets, USP 500mg | 212087 | 31-Jul-2020 | 100 counts in HDPE bottles 500 counts in HDPE bottles |
| 4 | Tacrolimus Capsules USP, 0.5, 1 and 5 mg | 213112 | 10-Nov-2020 | 100 counts in HDPE bottles |